"Markov Chains" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A stochastic process such that the conditional probability distribution for a state at any future instant, given the present state, is unaffected by any additional knowledge of the past history of the system.
| Descriptor ID |
D008390
|
| MeSH Number(s) |
E05.318.740.600.500 E05.318.740.996.500 G17.830.500 N05.715.360.750.625.500 N05.715.360.750.770.500 N06.850.520.830.600.500 N06.850.520.830.996.500
|
| Concept/Terms |
Markov Chains- Markov Chains
- Chains, Markov
- Markov Process
- Markov Processes
- Process, Markov
- Processes, Markov
- Markov Chain
- Chain, Markov
|
Below are MeSH descriptors whose meaning is more general than "Markov Chains".
Below are MeSH descriptors whose meaning is more specific than "Markov Chains".
This graph shows the total number of publications written about "Markov Chains" by people in this website by year, and whether "Markov Chains" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1998 | 1 | 1 | 2 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 4 | 4 |
| 2004 | 1 | 3 | 4 |
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 5 | 5 |
| 2008 | 1 | 6 | 7 |
| 2009 | 0 | 6 | 6 |
| 2010 | 0 | 6 | 6 |
| 2011 | 1 | 4 | 5 |
| 2012 | 1 | 6 | 7 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 6 | 6 |
| 2015 | 0 | 5 | 5 |
| 2016 | 0 | 4 | 4 |
| 2017 | 0 | 4 | 4 |
| 2018 | 0 | 6 | 6 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 5 | 5 |
| 2021 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Markov Chains" by people in Profiles.
-
Folding and misfolding of potassium channel monomers during assembly and tetramerization. Proc Natl Acad Sci U S A. 2021 08 24; 118(34).
-
Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. Gynecol Oncol. 2021 08; 162(2):249-255.
-
Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol. 2021 01 01; 116(1):125-133.
-
Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US. JAMA Netw Open. 2020 11 02; 3(11):e2023677.
-
Cyclic transitions between higher order motifs underlie sustained asynchronous spiking in sparse recurrent networks. PLoS Comput Biol. 2020 09; 16(9):e1007409.
-
Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. Gastroenterology. 2020 11; 159(5):1985-1987.e4.
-
Alternative type 2 diabetes screening tests may reduce the number of U.S. adults with undiagnosed diabetes. Diabet Med. 2020 11; 37(11):1935-1943.
-
Thyroidectomy for euthyroid patients with Hashimoto thyroiditis and persisting symptoms: A cost-effectiveness analysis. Surgery. 2021 Jan; 169(1):7-13.
-
Movement Decomposition in the Primary Motor Cortex. Cereb Cortex. 2019 04 01; 29(4):1619-1633.
-
Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer. JAMA Oncol. 2019 02 01; 5(2):236-242.